New CSF Biomarkers for Alzheimer's Disease

Alzheimer Disease Clinical Trial

— BioAD  

Official title:

New Diagnosis or Prognosis Biomarkers for Alzheimer's Disease: Biobank of CSF Collected as Part of Differential Diagnosis of Dementia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03621839
• Other study ID #: 2012-PSS/COLL- LCR/ARMAND/MS
• Status: Recruiting
• Start date: July 12, 2013
• Est. completion date: December 31, 2050

Study information

• Verified date: December 2023
• Source: Central Hospital, Nancy, France
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Today, the Alzheimer's disease (AD) diagnosis is founded not only on clinical criteria but also on complementary examinations to confirm a physiopathological process of AD. In complex cases, lumbar punction could be necessary in order to measure Aβ peptides and Total and phosphorylated Tau but new biomarkers could be useful. The main objective of this project is to conserve these cerebrospinal fluids, collected in usual practice in order to validate new biomarkers for diagnosis, prognosis or therapeutic following of Alzheimer's disease and other dementia.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50000
• Est. completion date: December 31, 2050
• Est. primary completion date: December 31, 2050
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Lumbar punction collected in usual practice in the context of dementia diagnosis

Exclusion Criteria:

• Absence of consent

Related Conditions & MeSH terms

• Alzheimer Disease
• Dementia
• Neurodegenerative Diseases

Locations

Country	Name	City	State
France	CHRU De Nancy	Nancy	Grand Est

Sponsors (1)

Lead Sponsor	Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CSF collection constitution to have samples available for assessing new Alzheimer's biomarker	Each CSF collected in the context of dementia diagnosis were conserved to be used in other studies on Alzheimer's or dementia biomarkers. Futre studies that will use collected CSF to assess new biomarkers will be conduced under a new protocol describing scientific contexte, specific aims and time frame necessary to achieve them.	50 years